TRAXENS
1.9.2020 08:32:05 CEST | Business Wire | Press release
Traxens, a company that provides high-value data and services for the supply chain industry, announces today a major partnership with COSCO Shipping Logistics that aims to promote a full set of IoT data services based on Traxens cutting-edge smart container solutions. Both companies are carrying out a test program to provide IoT data services to COSCO Shipping Logistics’ large worldwide base of beneficial cargo owners (BCO) customers and aiming to join force in promoting supply chain digitalization. This follows the opening of Traxens’ China office – its first outside of France.
COSCO is a leading global shipping company and a container logistics operator in China. In partnering with COSCO, Traxens will be able to demonstrate its capacity in creating customer values through promoting its smart container solutions and digital services, and significantly contributing to the ongoing digitalization of the global container logistics industry. As the global supply chain becomes more and more competitive, improved tracking and smart data management is an increasingly important differentiation factor for all the major players in the shipping industry.
Through this partnership, COSCO will be able to offer premium data services to its large base of BCOs who are seeking door-to-door visibility and ever-increasing efficiency in their supply chains. This joint development in container supply chain digitalization marks a milestone in Traxens’ international expansion strategy and will help the company push forward with further business development in Asia.
“Our main focus as a business is to be able to create substantial customer value by delivering superior solution and services through technological innovation and global customer support capacity” said David Marchand, Traxens CEO. “Our partnership with COSCO will greatly benefit cargo owners and end-users and encourage further digitalization of the container logistics industry to the benefit of customers worldwide.”
“Traxens is delighted to be working with COSCO, providing its industry-proven smart container solutions to help streamline the company’s operations and enhance customers experience,” said Vincent Gu, managing director, Traxens Asia-Pacific. “Providing fleets with global visibility, exception management and business intelligence is what Traxens does best. By partnering up with global shipping companies such as COSCO we are able to demonstrate what our market-leading IoT solutions are capable of, giving client companies end-to-end shipment visibility and predictive insights that will benefit the end-users and the whole industry.”
“Through our partnership with Traxens, we aim to be at the forefront of digitalization and to maintain our leadership in the global container logistics industry ” said Sheng Liu, general manager of the container logistics division of COSCO SHIPPING Logistics. “As a leading global logistics company, we always pay close attention to the needs of our customers in their supply chain. We believe that the IoT services developed by Traxens are important to improve tracking and management of moving assets.”
About COSCO Shipping
COSCO SHIPPING Logistics Co., Ltd (COSCO SHIPPING Logistics), affiliated to CHINA COSCO SHIPPING CORPORATION LIMITED, is an international integrated logistics enterprise with shipping logistics as its core. It can provide modernized and professional whole-process logistics and supply chain solutions for customers at home and abroad. With a strong reputation and professional service capabilities, it is an important partner for governments, ports, railways, airports and large multinational companies.
The company, with headquarters in Beijing, is merged with CHINA COSCO Logistics Co., Ltd.(a part of COSCO Group), China Shipping Logistics Co., Ltd. (China Shipping Group) and China Shipping Agency Co., Ltd. (China Shipping Group). It was launched on December 21, 2016. China Ocean Shipping Tally Company was incorporated into COSCO SHIPPING Logistics after integration on September 18, 2017.
The company’s service network covers 30 provinces in China and many other countries and regions in Europe, America, Asia and Africa. There are over 600 sales and service points throughout the world; such broad sales and service networks provide customers with a full range of logistics solutions. Since its establishment, COSCO Shipping Logistics has won the Golden Pegasus Prize and has for many years been recognised as one of the National Advanced Logistics Enterprises.
http://www.cosco-logistics.com.cn/
About Traxens
Traxens drives digital transformation in the global supply chain. The company’s breakthrough IoT technology, data science expertise, global logistics experience and standards leadership unlock the value of real-time data generated from cargo assets shipped by sea, rail and road. Traxens is trusted by hundreds of global cargo owners, enabling them to reduce door-to-door transport costs, optimize their investments and minimize risk. By partnering with the world’s leading shipping lines, rail carriers and smart ports, Traxens helps all members of the global supply chain ecosystem improve decision making, operations and customer service. Traxens is privately held and headquartered in Marseille, France.
www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005361/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom